{"id":813874,"date":"2025-02-18T06:23:05","date_gmt":"2025-02-18T11:23:05","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/enlivex-issues-urgent-statement-on-fraudulent-news-dissemination\/"},"modified":"2025-02-18T06:23:05","modified_gmt":"2025-02-18T11:23:05","slug":"enlivex-issues-urgent-statement-on-fraudulent-news-dissemination","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/enlivex-issues-urgent-statement-on-fraudulent-news-dissemination\/","title":{"rendered":"Enlivex Issues Urgent Statement on Fraudulent News Dissemination"},"content":{"rendered":"<div class=\"mw_release\">\n<p align=\"left\">Ness-Ziona, Israel, Feb.  18, 2025  (GLOBE NEWSWIRE) &#8212; Enlivex Therapeutics Ltd. (Nasdaq and TASE: ENLV, the \u201cCompany\u201d), a clinical-stage macrophage reprogramming immunotherapy company, alerts investors and the public that a completely false and misleading report regarding the Company was intentionally published this morning by the website <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=CCq_R8L-Jp9lXgrtzwcxcC3pXKy_CGasZ8dxzO4lme_P_DXQlwbDyUqyzIJTutXC_uAn4fyO4Xnp0LqGmO-vYw==\" rel=\"nofollow\" target=\"_blank\">Tipranks.com<\/a> claiming that the Company has suspended its stock trading due to an internal investigation.\u00a0\u00a0 These reports are completely unfounded and constitute fake news. The Company continues to operate normally, and its shares continue to trade regularly on the Tel Aviv Stock Exchange and NASDAQ Stock Exchange without any interruption.\u00a0\u00a0<\/p>\n<p align=\"justify\">The Company unequivocally denies the claims made in this false report and urges investors to rely only on official communications from the Company, including press releases, filings with the U.S. Securities and Exchange Commission, and statements from verified Company channels.<\/p>\n<p align=\"justify\">\u201cThis is a blatant attempt to manipulate public perception and mislead investors,\u201d said Oren Hershkovitz, the Company\u2019s CEO. \u201cWe take this matter very seriously and will pursue all available legal actions against the individuals responsible, including the publishers of the false report and the hosting service of <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=CCq_R8L-Jp9lXgrtzwcxcOknFD9SHKnAPm4SgtY-0x4jYK590nNBBVFsH_kYGat8zFr_3queEdNr1bX-nAyYFw==\" rel=\"nofollow\" target=\"_blank\">Tipranks.com<\/a>. We are continuing to execute our operating plan and are excited about the potential of Allocetra<sup>TM<\/sup> to offer treatment solutions to tens of millions of osteoarthritis patients, who have very poor treatment alternatives today.\u201d<\/p>\n<p align=\"justify\">Investors and stakeholders with concerns or questions are encouraged to contact Shachar Shlosberger, the Company\u2019s CFO.<\/p>\n<p align=\"left\">\n        <strong>ABOUT ENLIVEX<\/strong>\n      <\/p>\n<p align=\"left\">Enlivex is a clinical stage macrophage reprogramming immunotherapy company developing Allocetra\u2122, a universal, off-the-shelf cell therapy designed to reprogram macrophages into their homeostatic state. Resetting non-homeostatic macrophages into their homeostatic state is critical for immune system rebalancing and resolution of life-threatening conditions. For more information, visit\u00a0<a href=\"https:\/\/www.globenewswire.com\/Tracker?data=vmXKBY-nCWKx8QA1CGiYauBg26CW_ltyOsPkGOa7V8TfpmGRQqa19XNRLvMSlaHNfpjrJXoGALW2kAWXYcem_nU-htF5jxwvytfnesrGpmuE-pzMfLyYA62-oyuQhQ9EOLfsK0P9qb5LgnpfLOo3Qa_Czft1QVUJjL4Hp05NzaXwLKb82Y9Niz9eRvNE_xsZ7gsbtxkkN-dNmZwTWZgLiYSpuDwuOZ2uXfEuSeYDy4gDe0HNajd17xzp8cmeX2tJWjNuMd0Fkza7DNLh_O0UDzjtlVb2tiA9U0K9MIzL2k2X4XoubP4aSwBVZ1KW3NJkU2ZyEaLwl9H-UkkkCKXCJY4sxOtoQIQOdmSjGqH46YcAkY14BMhgUOjVqaTnqvdXebSS0PeGLAINB0pWmA7DZhYhOhy4f0XON3rQzUoRN6E9fx0Xqk1zOnVCYiqP7JLuqBwn053AiqftfLPicHO3a0aW5L5bT1EQ2eIh7buduamcumU_o3lNIVrUEyllvCUk3tWNZWPqAMDs0KyjptpZDpemvVL6IWkkeiM7RZ4lChcaeCkTbIN6FqLRI03a6B9MEmmx42zPD-eGS6oTX4IGQ7sfiAgipszrmmOJ_pQlMl9jcMMrIxNE6GqkYqTWoFAMmZ8hCVHdNSR4yFkWhf70KFmdpM6KEmXDHqf8rDCSlZA=\" rel=\"nofollow\" target=\"_blank\"><u>http:\/\/www.enlivex.com<\/u><\/a>.<\/p>\n<p align=\"left\">Safe Harbor Statement: This press release contains forward-looking statements, which may be identified by words such as \u201cexpects,\u201d \u201cplans,\u201d \u201cprojects,\u201d \u201cwill,\u201d \u201cmay,\u201d \u201canticipates,\u201d \u201cbelieves,\u201d \u201cshould,\u201d \u201cwould\u201d, \u201ccould,\u201d \u201cintends,\u201d \u201cestimates,\u201d \u201csuggests,\u201d \u201chas the potential to\u201d and other words of similar meaning, including statements regarding expected cash balances, market opportunities for the results of current clinical studies and preclinical experiments, the effectiveness of, and market opportunities for, ALLOCETRA<sup>TM<\/sup>\u00a0programs. All such forward-looking statements are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Investors are cautioned that forward-looking statements involve risks and uncertainties that may affect Enlivex\u2019s business and prospects, including the risks that Enlivex may not succeed in generating any revenues or developing any commercial products; that the products in development may fail, may not achieve the expected results or effectiveness and\/or may not generate data that would support the approval or marketing of these products for the indications being studied or for other indications; that ongoing studies may not continue to show substantial or any activity; and other risks and uncertainties that may cause results to differ materially from those set forth in the forward-looking statements. The results of clinical trials in humans may produce results that differ significantly from the results of clinical and other trials in animals. The results of early-stage trials may differ significantly from the results of more developed, later-stage trials. The development of any products using the ALLOCETRA<sup>TM<\/sup>\u00a0product line could also be affected by a number of other factors, including unexpected safety, efficacy or manufacturing issues, additional time requirements for data analyses and decision making, the impact of pharmaceutical industry regulation, the impact of competitive products and pricing and the impact of patents and other proprietary rights held by competitors and other third parties. In addition to the risk factors described above, investors should consider the economic, competitive, governmental, technological and other factors discussed in Enlivex\u2019s filings with the Securities and Exchange Commission, including in the Company\u2019s most recent Annual Report on Form 20-F filed with the Securities and Exchange Commission. The forward-looking statements contained in this press release speak only as of the date the statements were made, and we do not undertake any obligation to update forward-looking statements, except as required under applicable law.<\/p>\n<p align=\"left\">\n        <strong>ENLIVEX CONTACT<\/strong><br \/>\n        <br \/>Shachar Shlosberger, CFO<br \/>Enlivex Therapeutics, Ltd.<br \/><a href=\"https:\/\/www.globenewswire.com\/Tracker?data=mND4dsSDUvIuWIm8T-Pks-WjuwSaHjxFBpV0-ojqXuHUqnDBjO3w512DFD-LrCRMiGkJtxamllHmt0fiq7vpxrrjhVNxx2g5Uzj4qKhPasOSweU8ilGsPcvCZ9dSLmT2Sy87QdsOp16n3w_lQIF4mzQWvbbT8hgYNJLD9nX2epmY0j1-Nmck3P7aJhmvR4b_Ig44QEz5wHok6lK41BiMLskW81SILNEBi-PEDXsFfulnjvbcycut0kDOqJwJcsfhl1WI3tOaCKUAyr16h6yqXw==\" rel=\"nofollow\" target=\"_blank\"><u>shachar@enlivexpharm.com<\/u><\/a><\/p>\n<p align=\"left\">\n        <strong>INVESTOR RELATIONS CONTACT<\/strong><br \/>\n        <br \/>Dave Gentry, CEO<br \/>RedChip Companies Inc.<br \/>1-407-644-4256<br \/><a href=\"https:\/\/www.globenewswire.com\/Tracker?data=V5GLJhIcHPIgQe3GXrpEinr-TuJHkIL_mptbewUks1i1CpclkZR0vEuC-pY6p-JCR4ePqEtKl1oVvqsqc4Uhaw==\" rel=\"nofollow\" target=\"_blank\">ENLV@redchip.com<\/a><\/p>\n<p>      <img decoding=\"async\" alt=\"\" class=\"__GNW8366DE3E__IMG\" src=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTM2MDAyOSM2NzU1NTk2IzUwMDA2NTE3NA==\" \/><br \/>\n      <br \/>\n      <img decoding=\"async\" alt=\"\" src=\"https:\/\/ml.globenewswire.com\/media\/NGU3YzEzNTUtZTJiNy00NjNiLTg0MWMtYzY2NzcwZmI4ZjVhLTUwMDA2NTE3NA==\/tiny\/Enlivex-Therapeutics-Ltd.png\" \/>\n    <\/div>\n<div class=\"mw_contactinfo\"><\/div>\n","protected":false},"excerpt":{"rendered":"<p>Ness-Ziona, Israel, Feb. 18, 2025 (GLOBE NEWSWIRE) &#8212; Enlivex Therapeutics Ltd. (Nasdaq and TASE: ENLV, the \u201cCompany\u201d), a clinical-stage macrophage reprogramming immunotherapy company, alerts investors and the public that a completely false and misleading report regarding the Company was intentionally published this morning by the website Tipranks.com claiming that the Company has suspended its stock trading due to an internal investigation.\u00a0\u00a0 These reports are completely unfounded and constitute fake news. The Company continues to operate normally, and its shares continue to trade regularly on the Tel Aviv Stock Exchange and NASDAQ Stock Exchange without any interruption.\u00a0\u00a0 The Company unequivocally denies the claims made in this false report and urges investors to rely only on official communications from the Company, including &hellip; <\/p>\n<p class=\"link-more\"><a href=\"https:\/\/www.marketnewsdesk.com\/index.php\/enlivex-issues-urgent-statement-on-fraudulent-news-dissemination\/\" class=\"more-link\">Continue reading<span class=\"screen-reader-text\"> &#8220;Enlivex Issues Urgent Statement on Fraudulent News Dissemination&#8221;<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-813874","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.6 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Enlivex Issues Urgent Statement on Fraudulent News Dissemination - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/enlivex-issues-urgent-statement-on-fraudulent-news-dissemination\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Enlivex Issues Urgent Statement on Fraudulent News Dissemination - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"Ness-Ziona, Israel, Feb. 18, 2025 (GLOBE NEWSWIRE) &#8212; Enlivex Therapeutics Ltd. (Nasdaq and TASE: ENLV, the \u201cCompany\u201d), a clinical-stage macrophage reprogramming immunotherapy company, alerts investors and the public that a completely false and misleading report regarding the Company was intentionally published this morning by the website Tipranks.com claiming that the Company has suspended its stock trading due to an internal investigation.\u00a0\u00a0 These reports are completely unfounded and constitute fake news. The Company continues to operate normally, and its shares continue to trade regularly on the Tel Aviv Stock Exchange and NASDAQ Stock Exchange without any interruption.\u00a0\u00a0 The Company unequivocally denies the claims made in this false report and urges investors to rely only on official communications from the Company, including &hellip; Continue reading &quot;Enlivex Issues Urgent Statement on Fraudulent News Dissemination&quot;\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/enlivex-issues-urgent-statement-on-fraudulent-news-dissemination\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2025-02-18T11:23:05+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTM2MDAyOSM2NzU1NTk2IzUwMDA2NTE3NA==\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"3 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/enlivex-issues-urgent-statement-on-fraudulent-news-dissemination\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/enlivex-issues-urgent-statement-on-fraudulent-news-dissemination\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"Enlivex Issues Urgent Statement on Fraudulent News Dissemination\",\"datePublished\":\"2025-02-18T11:23:05+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/enlivex-issues-urgent-statement-on-fraudulent-news-dissemination\\\/\"},\"wordCount\":703,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/enlivex-issues-urgent-statement-on-fraudulent-news-dissemination\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTM2MDAyOSM2NzU1NTk2IzUwMDA2NTE3NA==\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/enlivex-issues-urgent-statement-on-fraudulent-news-dissemination\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/enlivex-issues-urgent-statement-on-fraudulent-news-dissemination\\\/\",\"name\":\"Enlivex Issues Urgent Statement on Fraudulent News Dissemination - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/enlivex-issues-urgent-statement-on-fraudulent-news-dissemination\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/enlivex-issues-urgent-statement-on-fraudulent-news-dissemination\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTM2MDAyOSM2NzU1NTk2IzUwMDA2NTE3NA==\",\"datePublished\":\"2025-02-18T11:23:05+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/enlivex-issues-urgent-statement-on-fraudulent-news-dissemination\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/enlivex-issues-urgent-statement-on-fraudulent-news-dissemination\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/enlivex-issues-urgent-statement-on-fraudulent-news-dissemination\\\/#primaryimage\",\"url\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTM2MDAyOSM2NzU1NTk2IzUwMDA2NTE3NA==\",\"contentUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTM2MDAyOSM2NzU1NTk2IzUwMDA2NTE3NA==\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/enlivex-issues-urgent-statement-on-fraudulent-news-dissemination\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Enlivex Issues Urgent Statement on Fraudulent News Dissemination\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Enlivex Issues Urgent Statement on Fraudulent News Dissemination - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/enlivex-issues-urgent-statement-on-fraudulent-news-dissemination\/","og_locale":"en_US","og_type":"article","og_title":"Enlivex Issues Urgent Statement on Fraudulent News Dissemination - Market Newsdesk","og_description":"Ness-Ziona, Israel, Feb. 18, 2025 (GLOBE NEWSWIRE) &#8212; Enlivex Therapeutics Ltd. (Nasdaq and TASE: ENLV, the \u201cCompany\u201d), a clinical-stage macrophage reprogramming immunotherapy company, alerts investors and the public that a completely false and misleading report regarding the Company was intentionally published this morning by the website Tipranks.com claiming that the Company has suspended its stock trading due to an internal investigation.\u00a0\u00a0 These reports are completely unfounded and constitute fake news. The Company continues to operate normally, and its shares continue to trade regularly on the Tel Aviv Stock Exchange and NASDAQ Stock Exchange without any interruption.\u00a0\u00a0 The Company unequivocally denies the claims made in this false report and urges investors to rely only on official communications from the Company, including &hellip; Continue reading \"Enlivex Issues Urgent Statement on Fraudulent News Dissemination\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/enlivex-issues-urgent-statement-on-fraudulent-news-dissemination\/","og_site_name":"Market Newsdesk","article_published_time":"2025-02-18T11:23:05+00:00","og_image":[{"url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTM2MDAyOSM2NzU1NTk2IzUwMDA2NTE3NA==","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"3 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/enlivex-issues-urgent-statement-on-fraudulent-news-dissemination\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/enlivex-issues-urgent-statement-on-fraudulent-news-dissemination\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"Enlivex Issues Urgent Statement on Fraudulent News Dissemination","datePublished":"2025-02-18T11:23:05+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/enlivex-issues-urgent-statement-on-fraudulent-news-dissemination\/"},"wordCount":703,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/enlivex-issues-urgent-statement-on-fraudulent-news-dissemination\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTM2MDAyOSM2NzU1NTk2IzUwMDA2NTE3NA==","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/enlivex-issues-urgent-statement-on-fraudulent-news-dissemination\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/enlivex-issues-urgent-statement-on-fraudulent-news-dissemination\/","name":"Enlivex Issues Urgent Statement on Fraudulent News Dissemination - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/enlivex-issues-urgent-statement-on-fraudulent-news-dissemination\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/enlivex-issues-urgent-statement-on-fraudulent-news-dissemination\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTM2MDAyOSM2NzU1NTk2IzUwMDA2NTE3NA==","datePublished":"2025-02-18T11:23:05+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/enlivex-issues-urgent-statement-on-fraudulent-news-dissemination\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/enlivex-issues-urgent-statement-on-fraudulent-news-dissemination\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/enlivex-issues-urgent-statement-on-fraudulent-news-dissemination\/#primaryimage","url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTM2MDAyOSM2NzU1NTk2IzUwMDA2NTE3NA==","contentUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTM2MDAyOSM2NzU1NTk2IzUwMDA2NTE3NA=="},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/enlivex-issues-urgent-statement-on-fraudulent-news-dissemination\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"Enlivex Issues Urgent Statement on Fraudulent News Dissemination"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/813874","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=813874"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/813874\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=813874"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=813874"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=813874"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}